Alejandra Tomás-Velázquez

Dr. Alejandra Tomás-Velázquez

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2018 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
EME Moreno-Artero
E Moreno-Artero
EQE Querol-Cisneros
E Querol-Cisneros
NRN Rodríguez-Garijo
N Rodríguez-Garijo
ATAlejandra Tomás-Velázquez
Alejandra Tomás-Velázquez
JAJAVIER ANTOÑANZAS
JAVIER ANTOÑANZAS
AEA España
A España

24 November 2021 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
ATAlejandra Tomás-Velázquez
Alejandra Tomás-Velázquez
OSOnofre Sanmartin-Jiménez
Onofre Sanmartin-Jiménez
JGJoan R. Garcés
Joan R. Garcés
MRManuel A. Rodríguez-Prieto
Manuel A. Rodríguez-Prieto
VRVerónica Ruiz-Salas
Verónica Ruiz-Salas
Pedro RedondoPedro Redondo
Pedro Redondo
Randomized studies to assess the efficacy of Mohs micrographic surgery in basal cell and squamous cell carcinomas are limited by methodological and ethical issues and a lack of long follow-up periods. This study presents the “real-life” results of a nationwide 7-years cohort on basal cell carcinoma and squamous cell carcinoma treated with Mohs micrographic surgery. A prospective cohort was conducted in 22 Spanish centres (from July 2013 to February 2020) and a multivariate analysis, including characteristics of patients, tumours, surgeries and follow-up, was performed. A total of 4,402 patients followed up for 12,111 patient-years for basal cell carcinoma, and 371 patients with 915 patient-years of follow-up for squamous cell carcinoma were recruited. Risk factors for recurrence included age, non-primary tumours and more stages or unfinished surgeries for both tumours, and immunosuppression for squamous cell carcinoma. Incidence rates of recurrence were 1.3 per 100 person-years for basal cell carcinoma (95% confidence interval 1.1–1.5) and 4.5 for squamous cell carcinoma (95% confidence interval 3.3–6.1), being constant over time (0–5 years). In conclusion, follow-up strategies should be equally intense for at least the first 5 years, with special attention paid to squamous cell carcinoma (especially in immunosuppressed patients), elderly patients, non-primary tumours, and those procedures requiring more stages, or unfinished surgeries.

1 February 2021 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Closed access
EQElena Querol‐Cisneros
Elena Querol‐Cisneros
EMEster Moreno‐Artero
Ester Moreno‐Artero
NRNuria Rodríguez‐Garijo
Nuria Rodríguez‐Garijo
ATAlejandra Tomás-Velázquez
Alejandra Tomás-Velázquez
IQIgnacio Querol
Ignacio Querol
AEAgustín España
Agustín España

29 December 2020 in Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
BRB. Recalde‐Zamacona
B. Recalde‐Zamacona
ATAlejandra Tomás-Velázquez
Alejandra Tomás-Velázquez
ACA. Campo
A. Campo
BSB. Satrústegui‐Alzugaray
B. Satrústegui‐Alzugaray
MFM. Fernández‐Alonso
M. Fernández‐Alonso
MAManuel F. Landecho Acha
Manuel F. Landecho Acha

29 August 2019 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
NRNuria Rodriguez‐Garijo
Nuria Rodriguez‐Garijo
EQElena Querol‐Cisneros
Elena Querol‐Cisneros
ATAlejandra Tomás-Velázquez
Alejandra Tomás-Velázquez
AEAngela Estenaga
Angela Estenaga
EMEster Moreno‐Artero
Ester Moreno‐Artero
AEAgustin España
Agustin España

1 November 2021 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
MCMaría Carmen Ceballos-Rodríguez
María Carmen Ceballos-Rodríguez
PRPedro Redondo
Pedro Redondo
ATAlejandra Tomás-Velázquez
Alejandra Tomás-Velázquez
DCDeysy Cieza-Díaz
Deysy Cieza-Díaz
JLJuan Carlos López-Gutiérrez
Juan Carlos López-Gutiérrez